Weak evidence on nalmefene creates dilemmas for clinicians and poses questions for regulators and researchers
Open accessThe DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Abstract
Background and aims: Nalmefene has been approved in Europe for the treatment of alcohol dependence and subsequently recommended by the UK National Institute for Health and Care Excellence (NICE). This study examines critically the evidence base underpinning both decisions and the issues arising. Methods: Published studies of nalmefene were identified through a systematic search, with documents from the European Medicines Agency, the NICE appraisal and public clinical trial registries also examined to identify methodological issues. Results: Efficacy data used to support the licensing of nalmefene suffer from risk of bias due to lack of specification of a priori outcome measures and sensitivity analyses, use of post‐hoc sample refinement and the use of inappropriate comparators. Despite this, evidence for the efficacy of nalmefene in reducing alcohol consumption in those with alcohol dependence is, at best, modest, and of uncertain significance to individual patients. The relevance of existing trial data to routine primary care practice is doubtful. Conclusions: Problems with the registration, design, analysis and reporting of clinical trials of nalmefene did not prevent it being licensed and recommended for treating alcohol dependence. This creates dilemmas for primary care clinicians and commissioning organisations where nalmefene has been heavily promoted, and poses wider questions about the effectiveness of the medicines regulation system and how to develop the alcohol treatment evidence base.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
SPIRIT 2013 Statement: Defining Standard Protocol Items for Clinical Trials
Chan, A.-W., Tetzlaff, J. M., Altman, D. G., Laupacis, A., Gøtzsche, P. C., Krleža-Jerić, K., Hróbjartsson, A., Mann, H., Dickersin, K., Berlin, J. A., et al. (2013) · Annals of Internal Medicine · doi:10.7326/0003-4819-158-3-201302050-00583 · Cited by 7,363
Review: a gentle introduction to imputation of missing values.
Donders, A. R. T., van der Heijden, G. J. M. G., Stijnen, T., & Moons, K. G. M. (2006) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2006.01.014 · Cited by 2,582
Systematic Review of the Empirical Evidence of Study Publication Bias and Outcome Reporting Bias
Dwan, K., Altman, D. G., Arnaiz, J. A., Bloom, J., Chan, A.-W., Cronin, E., Decullier, E., Easterbrook, P. J., Von Elm, E., Gamble, C., et al. (2008) · PLoS ONE · doi:10.1371/journal.pone.0003081 · Cited by 1,546 · cited 1×
“Clinical trial protocols should be registered publicly [41,42], with all outcome measures and associated timeframes specified fully to prevent selective reporting of favourable outcomes and unacknowledged changes to pre-specified measures [43,44].”
BackgroundStatistics in Medicine — Reporting of Subgroup Analyses in Clinical Trials
Wang, R., Lagakos, S. W., Ware, J. H., Hunter, D. J., & Drazen, J. M. (2007) · New England Journal of Medicine · doi:10.1056/nejmsr077003 · Cited by 1,445 · cited 1×
“Subgroup analyses normally involve pre-specifying levels of a baseline variable under investigation and testing for an interaction between the treatment and those levels, usually with a stricter level of significance [46].”
BackgroundJonas, D. E., Amick, H. R., Feltner, C., Bobashev, G., Thomas, K., Wines, R., Kim, M. M., Shanahan, E., Gass, C. E., Rowe, C. J., et al. (2014) · JAMA · doi:10.1001/jama.2014.3628 · Cited by 923
Preventing overdiagnosis: how to stop harming the healthy
Moynihan, R., Doust, J., & Henry, D. (2012) · BMJ · doi:10.1136/bmj.e3502 · Cited by 675 · cited 2×
“Se ns e [3 8] 67 5 ad ul ts w ith al co ho l”
BackgroundNaltrexone in the Treatment of Alcohol Dependence
Krystal, J. H., Cramer, J. A., Krol, W. F., Kirk, G. F., & Rosenheck, R. A. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011127 · Cited by 618
Johnson, M., Jackson, R., Guillaume, L., Meier, P., & Goyder, E. (2011) · Journal of Public Health · doi:10.1093/pubmed/fdq095 · Cited by 374 · cited 1×
“29–31), there have been long-standing implementation problems in primary care with much briefer interventions [66,67].”
BackgroundMcCambridge, J., Kypri, K., & Elbourne, D. (2014) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2013.09.004 · Cited by 138
Self-citationPalpacuer, C., Laviolle, B., Boussageon, R., Reymann, J. M., Bellissant, E., & Naudet, F. (2015) · PLOS Medicine · doi:10.1371/journal.pmed.1001924 · Cited by 102
Anderson, P., Wojnar, M., Jakubczyk, A., Gual, A., Reynolds, J., Segura, L., Sovinova, H., Csemy, L., Kaner, E., Newbury-Birch, D., et al. (2014) · Alcohol and Alcoholism · doi:10.1093/alcalc/agu043 · Cited by 83 · cited 1×
“However, many such pieces are authored or co-authored by those involved in the Lundbeck trials, in receipt of Lundbeck funding or who are company employees [68,70–82].”
BackgroundRegression to the mean in substance use disorder treatment research
Finney, J. W. (2008) · Addiction · doi:10.1111/j.1360-0443.2007.02032.x · Cited by 78
van Beurden, I., Anderson, P., Akkermans, R. P., Grol, R. P. T. M., Wensing, M., & Laurant, M. G. H. (2012) · Addiction · doi:10.1111/j.1360-0443.2012.03868.x · Cited by 73
Cited by
Diagnosis and Pharmacotherapy of Alcohol Use Disorder: A Review
Kranzler, H. R., & Soyka, M. (2018) · JAMA · doi:10.1001/jama.2018.11406 · Cited by 580
Palpacuer, C., Duprez, R., Huneau, A., Locher, C., Boussageon, R., Laviolle, B., & Naudet, F. (2018) · Addiction · doi:10.1111/add.13974 · Cited by 172
Reduced Drinking in Alcohol Dependence Treatment, What Is the Evidence?
Mann, K., Aubin, H.-J., & Witkiewitz, K. (2017) · European Addiction Research · doi:10.1159/000481348 · Cited by 93
Metadata
- Authors
- Fitzgerald, N., Angus, K., Elders, A., de Andrade, M., Raistrick, D., Heather, N., & McCambridge, J.
- Venue
- Addiction
- Publisher
- Wiley
- Published
- 2016-06-05
- Volume
- 111
- Issue
- 8
- Pages
- 1477-1487
- ISSN
- 0965-2140 (ISSN-L)
- 1360-0443
- OpenAlex
- W2410863731
- Cited by
- 45
- References
- 13
- FWCI
- 6.54
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.